CONMED Corp. Stock
CONMED Corp. Stock
CONMED Corp. dominated the market today, gaining €1.20 (3.800%).
Currently there is a rather positive sentiment for CONMED Corp. with 5 Buy predictions and 0 Sell predictions.
With a target price of 53 € there is a hugely positive potential of 61.59% for CONMED Corp. compared to the current price of 32.8 €.
Pros and Cons of CONMED Corp. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | 3.800% | -0.606% | 3.145% | -26.457% | -6.286% | -68.762% | -70.182% |
| Bio-Rad Labs Inc. A | -6.450% | -2.591% | 2.427% | 9.463% | -6.708% | -39.639% | -54.604% |
| Glaukos Corp | 0.970% | -0.952% | 10.053% | 24.551% | 7.772% | 146.445% | 37.748% |
| Integra LifeSciences Holdings Corp | 1.710% | -5.319% | 8.537% | -38.621% | -16.038% | -83.208% | -85.528% |
Comments
CONMED (CNMD) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (CNMD) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (NYSE:CNMD) had its price target lowered by analysts at Piper Sandler from $68.00 to $55.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat